AU
UK
CA
NZ
IND
US
Last update at 2026-06-22T18:14:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 17.16M | 2.96M | 12.68M | 11.48M | 11.06M |
| Minority interest | - | - | - | - | - |
| Net income | 27.33M | 11.54M | 20.38M | 26.64M | 7.76M |
| Selling general administrative | 16.30M | 12.24M | 5.42M | 5.54M | 5.11M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 40.42M | 24.10M | 17.09M | 16.68M | 18.26M |
| Reconciled depreciation | 7.23M | 4.02M | 1.23M | 0.99M | 0.70M |
| Ebit | - | - | - | 11.09M | 11.82M |
| Ebitda | - | - | - | 12.07M | 12.52M |
| Depreciation and amortization | - | - | - | 0.99M | 0.70M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 16.86M | 7.85M | 10.30M | 11.09M | 11.82M |
| Other operating expenses | - | - | - | 9.62M | 10.13M |
| Interest expense | - | - | - | 0.39M | 0.09M |
| Tax provision | -10.16600M | -8.59000M | -7.70200M | -15.15700M | 3.30M |
| Interest income | - | 0.33M | 1.87M | - | 0.01M |
| Net interest income | -1.16500M | 0.33M | 1.87M | 0.46M | -0.08000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | - | - | -15.15700M | 3.30M |
| Total revenue | 50.45M | 33.36M | 21.16M | 20.68M | 21.94M |
| Total operating expenses | 33.59M | 25.52M | 10.86M | 5.63M | 6.45M |
| Cost of revenue | 10.03M | 9.26M | 4.07M | 3.99M | 3.68M |
| Total other income expense net | 1.46M | -5.22300M | 0.51M | 0.39M | -0.76200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 27.33M | 11.54M | 20.38M | 26.64M | 7.76M |
| Net income applicable to common shares | - | - | - | 26.64M | 7.76M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 156.50M | 162.51M | 86.03M | 73.78M | 51.65M |
| Intangible assets | 72.01M | 78.75M | 1.76M | 2.75M | 3.65M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.16M | 0.99M | 0.38M | 0.37M | 0.47M |
| Total liab | 30.26M | 60.17M | 5.51M | 9.70M | 12.75M |
| Total stockholder equity | 126.24M | 102.34M | 80.52M | 64.08M | 38.90M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | - | - | 4.90M | 6.23M |
| Common stock | - | - | - | 17.72M | 18.12M |
| Capital stock | 27.86M | 27.68M | 18.01M | 17.72M | 18.12M |
| Retained earnings | 100.11M | 77.65M | 66.27M | 50.52M | 25.20M |
| Other liab | - | - | - | - | - |
| Good will | 17.45M | 17.45M | 15.71M | 15.71M | 15.71M |
| Other assets | - | - | - | 16.67M | 2.47M |
| Cash | 7.49M | 17.84M | 39.83M | 28.84M | 20.55M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 25.04M | 19.87M | 5.25M | 9.37M | 12.29M |
| Current deferred revenue | - | - | - | 0.26M | 0.45M |
| Net debt | - | 22.16M | - | -28.40800M | -20.03200M |
| Short term debt | - | - | - | 0.10M | 0.06M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | 0.43M | 0.52M |
| Other stockholder equity | - | - | - | 5.36M | 5.09M |
| Property plant equipment | - | - | - | 0.48M | 0.50M |
| Total current assets | 28.05M | 38.48M | 48.27M | 38.16M | 29.33M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 45.62M | 19.54M |
| Short term investments | - | - | - | - | - |
| Net receivables | 11.21M | 13.86M | 5.09M | 6.80M | 6.66M |
| Long term debt | 5.00M | 40.00M | - | - | - |
| Inventory | 8.19M | 5.79M | 2.98M | 2.15M | 1.65M |
| Accounts payable | 6.39M | 5.87M | 4.64M | 4.11M | 5.55M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -9.51400M | -9.51400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 128.46M | 124.03M | 37.76M | 35.62M | 22.32M |
| Capital lease obligations | 0.51M | 0.58M | 0.35M | 0.43M | 0.52M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -80.04400M | -0.14400M | -0.08100M | 0.00000M |
| Change to liabilities | - | - | - | -1.64100M | -1.08800M |
| Total cashflows from investing activities | - | - | - | -0.08100M | -0.08100M |
| Net borrowings | -35.30600M | 39.79M | -0.11100M | -0.05800M | -0.82800M |
| Total cash from financing activities | -40.47200M | 39.30M | -5.24400M | -1.91400M | -2.47000M |
| Change to operating activities | - | - | - | 0.10M | 0.37M |
| Net income | 27.33M | 16.51M | 27.55M | 26.64M | 7.76M |
| Change in cash | -10.81700M | -21.20200M | 10.61M | 8.29M | 11.41M |
| Begin period cash flow | 17.84M | 39.83M | 28.84M | 20.55M | 9.14M |
| End period cash flow | 7.49M | 17.84M | 39.83M | 28.84M | 20.55M |
| Total cash from operating activities | 29.73M | 19.55M | 16.00M | 10.57M | 13.81M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | - | - |
| Depreciation | 7.23M | 4.02M | 1.23M | 0.99M | 0.70M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -2.39800M | 3.60M | -0.83000M | -0.50200M | -0.75800M |
| Change to account receivables | 2.65M | -8.77200M | 1.71M | -0.14400M | 2.56M |
| Sale purchase of stock | -5.38100M | -0.17600M | -5.55900M | -1.98800M | -1.71700M |
| Other cashflows from financing activities | - | - | - | 0.13M | 0.07M |
| Change to netincome | - | - | - | -14.01600M | 0.68M |
| Capital expenditures | 0.20M | 0.04M | 0.14M | 0.08M | 0.08M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 5.23M | 8.95M | -3.27600M | -3.03400M | 4.68M |
| Stock based compensation | 1.74M | 1.07M | 1.19M | 0.40M | 0.14M |
| Other non cash items | 0.19M | 0.10M | -0.01000M | -0.10900M | 0.65M |
| Free cash flow | 29.52M | 19.50M | 15.86M | 10.49M | 13.81M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CPHRF Cipher Pharmaceuticals Inc |
0.05 0.44% | 11.46 | 12.81 | 14.18 | 6.77 | 2.68 | 6.72 | 14.07 |
| ZTS Zoetis Inc |
-2.82 3.58% | 75.89 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.19 0.62% | 30.56 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 157.12 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| GALDY GALDERMA GROUP AG |
- -% | 42.94 | 74.21 | 41.67 | 8.64 | 5.55 | 9.15 | 42.22 |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company's licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C. Its pipeline products include piclidenoson CF-101, a novel chemical entity for moderate to severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; and DTR-001, a tattoo removal cream. The company was founded in 2000 and is headquartered in Mississauga, Canada.
5750 Explorer Drive, Mississauga, ON, Canada, L4W 0A9
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig J. Mull | Interim CEO & Chairman | NA |
| Dr. Diane Gajewczyk | VP of Scientific & Medical Affairs | NA |
| Mr. Bryan Jacobs | Chief Financial Officer | NA |
| Mr. Emilio Presti | Director of Sales, Marketing & Hospital Bus. | NA |
| Chuoru Li | Corp. Controller | NA |
| David Miller | Director of Fin. | NA |
| Mr. Craig J. Mull | Interim CEO & Chairman of the Board | NA |
| Mr. Bryan Jacobs | President | NA |
| Mr. Ryan Mailling | Chief Financial Officer | NA |
| Mr. Emilio Presti | Director of Sales & Marketing | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...